Principal Investigator: Darren Brenner, MD Intestinal bacterial overgrowth (IBO) occurs when excessive amounts of bacteria build up in the small intestine (which is usually nearly sterile). These bacteria ferment ingested food, producing hydrogen, methane, and carbon dioxide. These intestinal gases can induce GI symptoms, including abdominal pain, bloating, distention, diarrhea, and constipation. Antibiotics often help, but for some patients, disruptive digestive symptoms will persist. IBO is subcategorized into two types: 1.) small intestinal bacterial overgrowth and 2.) intestinal methanogenic overgrowth. Recent studies suggest that increased methane production may come from the overgrowth of a specific type of bacteria. No current therapies exist to treat methane predominate IBO. An initial study of the herbal supplement Atrantil has shown promise. Investigating the potential benefit of this “holistic” treatment, Dr. Brenner will conduct a trial of Atrantil in 30 patients at the Northwestern Medicine Digestive Health Center. Researchers will evaluate Atrantil’s impact on reducing methane levels, lessening symptoms, and enhancing quality of life. The team believes Atrantil could offer an inexpensive and safe treatment for...
Principal Investigator: Josh Levitsky, MD | Co-Principal Investigator: Imran Nizamuddin, MD Primary sclerosing cholangitis (PSC) causes chronic inflammation of the bile ducts and, over time, potential liver failure. What triggers PSC and how it is strongly linked to ulcerative colitis (UC) remains unclear. One theory is that a “leaky gut” allows toxic compounds from the intestines to erroneously enter the liver. Dr. Levitsky’s team intends to test this theory by measuring intestinal permeability in PSC patients. Intestinal permeability (leakiness) can be studied by comparing absorption of different simple sugar solutions. Study participants will drink several sugar solutions to compare absorption and elimination in the urine. Researchers anticipate that the sugar levels in the urine will be different between patients with PSC, patients with PSC and ulcerative colitis, and healthy patients. If this occurs, the team will evaluate therapies, such as antibiotics, to assess their impact on the “leaky gut.” This project may serve as an initial step toward developing personalized treatment options for patients who currently don’t have any therapeutic options—currently a high unmet need in the field of...
